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g-Secretase proteases have been associated with pathology in Alzheimer disease (AD), but we are
just beginning to understand their basic mechanisms and physiological roles. A negative drug trial
with a broad spectrum g-secretase inhibitor in AD patients has severely dampened enthusiasm for
the potential of pursuing g-secretase research therapeutically. This pessimism is unwarranted:
analysis of available information presented here demonstrates significant confounds for interpret-
ing the outcome of the trial and argues that the major lessons pertain to broad knowledge gaps that
are imperative to fill.Rising too fast to fame is dangerous for
artists, scientists, politicians, and is now
the unhappy fate of the y-secretases.
These proteases have been eagerly
investigated by pharmaceutical com-
panies, as inhibitors would block the
production of amyloid b-peptide (Ab),
widely thought to play a key pathological
role in Alzheimer disease (AD) (Haass
and Selkoe, 1998). Recently, however,
g-secretase research has fallen into
disgrace because a phase III clinical trial
testing the inhibitor semagacestat failed
dramatically (Doody et al., 2013) leading
to abrupt closure of promising lines of
g-secretase work. Unfortunately, this
effect has not been limited to industry,
but has also cast a shadow over
research agendas in academia. In this
essay I present arguments for why the
takehome message of the semagacestat
trial should be the exact opposite, par-
ticularly in light of the prodigious evi-
dence for the relevance of g-secretase
in physiology and disease (Jurisch-Yaksi
et al., 2013). The field (and its granting
bodies) should instead learn from the trial
what is needed to fill our huge knowl-
edge gaps, and the pharmaceutical in-
dustry must be persuaded to sustain
their interest.
A Hasty Start
The semagacestat trial by Eli Lilly is sig-
nificant as an example of how we aremoving forward to treat AD in a rational
way. All the trial data have been made
available to the community. However, it
may be argued that the study was prema-
ture for several reasons. g-Secretase
inhibitors had become the subject of
intense focus in pharmaceutical research
many years ago because they were
readily identified in screens for com-
pounds that lower Ab cleavage in various
cell lines (Haass et al., 1992). Only several
years later were the proteases respon-
sible for the release of Ab identified (De
Strooper et al., 1998; Vassar et al.,
1999). With very little knowledge of the
biology of g-secretases, compounds
were pushed forward as drug candi-
dates. Lack of structure-function infor-
mation on the different g-secretases, no
understanding of how they interact with
their many substrates, and simplistic
assumptions on their physiology have
without any doubt hampered progress
of the field.
Semagacestat was one out of the many
candidate drugs that advanced as a
g-secretase inhibitor blocking Ab genera-
tion in cell cultures, animals, and finally
human. Only relatively late in the studies
did it become clear that the potential
side effects caused by blocking Notch-
signalingwere severely limiting the clinical
use of semagacestat (Henley et al., 2014).
In fact, from a scientific point of view, it
remains puzzling why the companyCell 159,decided to move forward toward phase
III tests (Doody et al., 2013) with a dose
(maximal 140 mg/day) that in none of the
phase II tests had shown any significant
impact on Ab levels in the cerebrospinal
fluid (CSF) of humans (Karran and Hardy,
2014). Looking back, it seems clear that
such a phase III trial was unlikely to test
the amyloid hypothesis, as elaborated
below.
Dosing, Kinetics, Toxicity, and
Cognitive Decline
The really unexpected finding of the trial
was that the patients actually experienced
cognitive decline as assessed by two
clinical scoring systems (Doody et al.,
2013). This toxic effect remains unex-
plained but is cited repeatedly as a major
counter argument against the further
development of g-secretase inhibitors.
The interpretation of the cognitive alter-
ations is complicated, however, and de-
serves in depth analysis and further
research before jumping to such a drastic
conclusion.
Based on the fact that chronic but
partial lowering of g-secretase activity
causes no major phenotypes in heterozy-
gote mice mutated in one of the g-secre-
tase genes (see for instance Ma et al.,
2005; Serneels et al., 2005), one would
expect that a chronic, moderate lowering
of this enzymatic activity in human could
be tolerated. Unfortunately, the trial didNovember 6, 2014 ª2014 Elsevier Inc. 721
Figure 1. Theoretical Flucutations of Semagacestat in CSF of Patients
The pharmacokinetic curve for semagacestat is modeled based on measurements and figure 2 in
(Bateman et al., 2009), using the data for the 140mgdose. The thresholds for Ab induction (black lines) and
Notch inhibition (red line) are only illustrative as the critical concentrations for these effects in human in vivo
are not known. As discussed in the text, the IC50 for g-secretase in cell culture is 5.9 ng/ml while the
maximum concentration reached in the CSF was 194 ng/ml. The bar below the figure shows the fluctu-
ations in g-secretase activity under this drug treatment: black blocks indicate stimulation (i.e. increased Ab
generation) while red blocks indicate complete inhibition of g-secretases. The precise scale of these
effects is not known and the figure is only meant to illustrate the strong oscillations in g-secretase activity
that were induced by the drug treatment in the trial.not test this hypothesis, but tested, as ex-
plained below, the effects of short peaks
of complete g-secretase inhibition in the
brain alternated with periods of normal
activity (Figure 1). This problem was
accentuated by the fact that the fear of
side effects led the investigators to dose
the drug just once a day, rather than the
twice a day regimen originally planned.
These bursts of full inactivation are likely
problematic. Indeed, severe Notch phe-
notypes are seen after complete genetic
inactivation of g-secretases in mice
(Bammens et al., 2011; Li et al., 2003;
Saura et al., 2004; Shen et al., 1997).
Notch signaling is part of ultradian oscilla-
tions, best studied in somitogenesis
(Kageyama et al., 2010) but also involved
in neuronal stem cell differentiation (Ka-
geyama et al., 2009). Short pulses of
full inhibition could have disastrous
effects in such oscillating systems. Notch
signaling oscillations have indeed been
implicated in memory formation (Ables
et al., 2011; Alberi et al., 2011; Zhang
et al., 2013), potentially explaining at least
part of the cognition problems in the
treated patients. It must be said that
misprocessing of other g-secretase sub-722 Cell 159, November 6, 2014 ª2014 Elsevstrates like N-cadherin, syndecan, neure-
gulin etc, could also contribute to the
problem, but little is known about whether
and how their misprocessing is related to
cognition and memory processes. In any
event, the tantalizing question arises
whether a more moderate but continuous
inhibition of g-secretase would have pre-
served such ultradian signaling mecha-
nisms to an extent sufficient to avoid the
adverse effects on cognition observed
now in the trial.
A second critical and important ques-
tion is to what extent confounding factors
contributed to the cognitive alterations in
these patients. g-secretase activity was
very strongly inhibited in peripheral tis-
sues during the trial and many of the
patients showed skin problems, weight
loss, vomiting, etc. (Doody et al., 2013).
These already frail Alzheimer patients
might have underperformed in those tests
simply because they felt sick from the
treatment. Again, lower dosing of the
drug in a more chronic regimen would
have avoided part of this peripheral
toxicity and patients probably would
have felt better. The issue that side effects
of test medication might compromiseier Inc.the interpretation of cognitive assays
certainly needs further scrutiny as it could
lead to the premature arrest of other
promising drug development programs
in the Alzheimer field for the wrong
reasons.
These peripheral side effects may
reflect the strong inhibition of Notch
signaling and maybe other g-secretase
substrates in all tissues. It has been
observed that the oral dosing used in
the trial yields very high ( 2,160 ng/ml)
concentrations for drug in plasma (Yi
et al., 2010). The half maximal inhibitory
concentration (IC50 of semagacestat) for
g-secretase inhibition in cell culture is
5.9 ng/ml (Bateman et al., 2009). It is
therefore likely that complete Notch inhi-
bition was achieved in a number of pe-
ripheral organs for relatively long periods.
Obviously the one-dose/day regimen also
resulted in drug free periods, and it can
be argued that these are beneficial in
the context of g-secretase treatment.
Indeed, continuous inhibition of g-secre-
tases might result in toxic accumulation
of its direct substrates like the APP car-
boxyterminal fragments (Mitani et al.,
2012). However, it seems very likely that
the complete inhibition of g-secretase
during the peak periods caused by the
one-a-day dosing contributed to exten-
sive side-effects.
The effects on the brain deserve sepa-
rate discussion. In the trial no effects on
Ab levels in the CSF were recorded
(Doody et al., 2013). Isotope labeling ki-
netics experiments indicated, however,
that with one dose of 140 mg semagace-
stat, the rate of Ab generation in the brain
would be inhibited by 52% over a 12 hr
time period (Bateman et al., 2009). In
these experiments it was also found that
peak drug concentrations of 194 ng/ml
were reached in the CSF (Bateman
et al., 2009). Although the IC50 in vivo is
not known, it can be safely assumed
based on the cellular IC50 that during
the trial and with this dose almost
complete inhibition of all g-secretase ac-
tivity in the brain was reached albeit for
short periods (Figure 1). Additional mea-
surements of alternative Ab1-15/16 frag-
ments in the CSF further indicated that
g-secretase is indeed inhibited in the
brain under the conditions of the trial
(Portelius et al., 2012). On the other
hand, given the rather short half-life of
Figure 2. The Semegacestat Clinical Trial: Taking the Glass Half-Full Perspectivesemagacestat (t1/2 2–3 hours), a single
dose of the drug is completely removed
from CSF after 12 hr (Bateman et al.,
2009).
From this brief overview it can be
deduced (1) that most of the day, patients
had no drug in the brain and produced
normal amounts of Ab; (2) each day pa-
tients went through a drug concentration
cycle, twice hitting a critical low concen-
tration of drug that is known, as explained
below, to paradoxically stimulate Ab
secretion; and (3) this treatment regimen
generated sharp oscillations in g-secre-
tase activity (Figure 1) that probably also
affected the kinetics of Ab generation. It
should be mentioned that inhibition of
Notch signaling might have exacerbated
the situation. Very different estimates
have been published for the selectivity of
semagacestat toward amyloid precursor
protein (APP) versus Notch (Karran and
Hardy, 2014), but from a quantitative cell
free assay with which IC50 could be
directly compared, it appears that sema-
gacestat has an intrinsic bias toward
inhibiting Notch cleavage (IC50APP/
IC50Notch: 0.1) (Cha´vez-Gutie´rrez et al.,
2012). Other g-secretase inhibitors in-
cluding avagacestat also turn out to be
far less selective for APP versus Notch
processing (Cha´vez-Gutie´rrez et al.,
2012; Crump et al., 2012) than sometimes
claimed (Probst et al., 2013). Therefore
novel drugs in the future should be pro-
filed more carefully against Notch but
also versus the other different substrates
of g-secretase.Steady-State Levels of AbWere Not
Lowered in the Brain
As mentioned, the observation that Ab
levels were not affected in the CSF is
very puzzling. It could be argued that
most of the time g-secretase activities
were not inhibited in the patients, and
that therefore no extreme effects on Ab
levels in the CSF were anticipated. How-
ever, one would still predict a lowering of
Ab if semagacestat would have worked
as a classical protease inhibitor. The
terminology ‘‘inhibitor’’ is in fact quite
misleading. Semagacestat targets an un-
characterized allosteric mechanism that
affects Ab generation in a biphasic way
causing a significant increase in Ab
release at low concentrations (Lanz
et al., 2006). Thus, in the pulsed drug
regimen used in the trial, patients would
have experienced transient periods of
increased Ab-generation twice a day
(Figure 1), which might have neutralized
further the effects on Ab in the CSF, and
might have led to a ‘‘zero-sum game’’.
Transient increases in Ab peptides
might have caused toxic effects although
this is speculative. Yet another confound-
ing problem, however, is that semagace-
stat affects generation of the Ab40 peptide
product more than that of Ab42 (Lanz
et al., 2004; Lanz et al., 2006). This was
confirmed in the plasma samples of the
patients in the trial: Ab40 was down by
48% while Ab42 decreased only by 18%
(Doody et al., 2013). This increase in
Ab42/Ab40 ratio while lowering the total
Ab load mimics the effects of several ge-Cell 159,netic mutations in g-secretase which
cause inherited Alzheimer disease (Cha´-
vez-Gutie´rrez et al., 2012). Relatively
small alterations in the ratio strongly influ-
ence toxic and aggregation properties of
Ab peptide mixes (Kuperstein et al.,
2010; McGowan et al., 2005). While it re-
mains unclear whether this effect was
played out in the brain of the patients dur-
ing the few hours per day that g-secretase
activity was affected, it is very clear that
semagacestat was not a simple inhibitor
of g-secretase activity and that the effects
on Ab in the brain were complex.
A New Deal for g-Secretase
Research
The thought pendulum in the field
regarding the critical pathological factor
in AD has been shifting slowly away from
the amyloid hypothesis toward Tau,
inflammation, and vascular problems.
However, it is premature to move com-
pletely into other directions, and different
approaches should not be considered
mutually exclusive. The arguments that
causally link Ab peptides to the disease
are strong (Karran et al., 2011), and it
therefore remains mandatory to test the
amyloid hypothesis exhaustively in the
clinic. The reasons behind the failures of
the semagacestat and other amyloido-
centric phase III trials are, as discussed
here and elsewhere (Karran and Hardy,
2014), quite complicated. We need to
thoroughly address the many new ques-
tions that are arising if we want to make
real scientific progress (Figure 2). More
time for our thinking to mature and to
evaluate different clinical hypotheses
in smaller clinical trials seems a prerequi-
site to make the best out of the few
options for treatment that are currently
available. However, even more important
at this moment is profound basic
research. Although only recognized by
few, the current knowledge gap in g-sec-
retase biology, physiology, and structural
biology is appallingly wide. Novel insights
and deeper understanding of these en-
zymes will provide a basis for more
rational drug design and for a less specu-
lative analysis of results obtained in
clinical trials. It is also likely that such
work will broaden the scope of potential
applications, i.e., in acute leukemia (Groth
and Fortini, 2012), or, unexpectedly, as a
topical treatment for regeneration of innerNovember 6, 2014 ª2014 Elsevier Inc. 723
ear hair cells after acoustic trauma (Mizu-
tari et al., 2013).
Back to the Basics
g-Secretases are indeed very intriguing
molecular machines. We know for
instance that they consist of four protein
subunits (presenilin, nicastrin, presenilin
enhancer 2, and anterior pharynx 1) en-
coded by four different genes (PSEN,
NCT, PEN2, and APH1) (De Strooper,
2003), but we still do not understand
why the presenilin subunits need the other
subunits to become catalytically active.
This question is not trivial as their full
cousins, the signal peptide peptidases
(SPPs) (Grigorenko et al., 2002; Ponting
et al., 2002; Weihofen et al., 2002) are fully
active as single proteins or as homomul-
timers (Li et al., 2013; Miyashita et al.,
2011; Nyborg et al., 2004 reviewed in
Voss et al., 2013). It has been also very
misleading to discuss g-secretases as
if they were one protease, which has
been stated in most of the available litera-
ture. Four major variant complexes are
generated with the two different PSEN
and two different APH1 subunits (De
Strooper, 2003), and additional com-
plexity comes from alternative splicing of
the subunits. Semagacestat, as well as
other clinically tested inhibitors such as
avagacestat, might block all different
g-secretase complexes indiscriminately
which might contribute to the overall
toxicity of these drugs. Also the question
of the specific function of the different en-
zymes remains hardly explored (Serneels
et al., 2009), although we already know
that major toxic effects caused by such
broad spectrum g-secretase inhibitors
can be circumvented in mice when using
more selective compounds (Borgega˚rd
et al., 2012).
The fundamental cell biology of the
g-secretase complexes needs a revival:
how does the differential composition of
the complexes determine subcellular,
cellular and tissue distribution of the
g-secretases? Can a specific localization
of the complexes in specific membrane
compartments be related to specificity
toward different substrates? Given the
critical roles of g-secretases in the
synapse (Zhang et al., 2009), cell biolog-
ical questions are particular relevant
in the context of the neuron with its
long axons and complex dendritic com-724 Cell 159, November 6, 2014 ª2014 Elsevpartments. Evidence links conformational
changes in g-secretase with synaptic
electrical activity and Ab generation
(Dolev et al., 2013). Ultimately the link
between brain activity, functions of g-sec-
retases, and alterations in Ab production
is one of the real core questions in the
field.
Additionally, it is key to understand
what are the physiologically relevant sub-
strates of g-secretases. A number have
been proposed and this promiscuity is
often cited as a rationale against the
development of g-secretase inhibitors,
but with very little knowledge about which
substrates matter in vivo. This lack of
basic understanding of the function of
such important enzymes renders the
interpretation of the results obtained in
clinical trials virtually impossible, and bet-
ter understanding will lead to more effec-
tive and safer drug candidates.
Another path to greater understanding
and better drug development is struc-
tural insights. This has been challenging
but progress is underway: Last year
Shi and collaborators provided a first
ultrastructure of a presenilin homologue
(Li et al., 2013). This year the same
group, using single particle cryoelectron
microscopy, published a structure of
an entire g-secretase complex at 4.5
Angstrom resolution, and a higher reso-
lution map of the nicastrin subunit based
on its similarity to a glutamate carboxy-
peptidase (Lu et al., 2014). These are
major steps forward, although we need
even higher resolution to provide full
atomic detail.
A Bright Future
It is clear that exciting times for g-secre-
tases are ahead of us. Progress in the
areas discussed above will allow us
to understand in precise detail how ge-
netic mutations causing AD affect the
function of these enzymes. They also
will provide real insight in how drugs
like semagacestat target allosteric sites
in the complexes and how this modu-
lates their activities. This will facilitate
optimization of the g-secretase modula-
tors still under clinical development.
Finally, we might be able to understand
how different substrates dock into
different g-secretases and to generate
very specific compounds that only inter-
fere with APP processing and not withier Inc.the processing of other substrates. It is
clear that the currently prevailing pessi-
mism in the g-secretase field is not
warranted. While we need the help
from investors, government, and public
opinion to achieve our goals, the first
and major drive for progress is the
conviction and enthusiasm of the re-
searchers, the pioneers that try to chart
the many unknowns and uncertainties in
this difficult but very important area of
Alzheimer disease research.
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